Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) recorded quarterly FCF Margin of 8876.39% in Q4 2024, up 188.87% quarter-over-quarter from 9988.22% in Q3 2024, and up 885902.0% on a YoY basis from N/an in Q1 2024.
Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' FCF Margin history runs 4 years deep, the most recent figure standing at 8876.39% for Q4 2024.
- In Q4 2024, FCF Margin rose 885902.0% year-over-year to 8876.39%; the TTM figure through Sep 2025 stood at 23236.09% (up 2329365.0% YoY), while the FY2024 annual figure was 192.06%, down 19486.0% from the prior year.
- FCF Margin was 8876.39% for Q4 2024 at Amylyx Pharmaceuticals, up from 9988.22% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 8876.39% in Q4 2024 to a low of 9988.22% in Q3 2024.
- Historically, FCF Margin has averaged 2107.46% across 4 years, with a median of 6.29% in 2023.
- Biggest YoY gain for FCF Margin was 885902 bps in 2024; the steepest drop was 998284 bps in 2024.
- A 4-year view of FCF Margin shows it stood at 7374.74% in 2021, then jumped by 97 bps to 232.06% in 2022, then jumped by 107 bps to 17.37% in 2023, then soared by 51002 bps to 8876.39% in 2024.
- The last three FCF Margin figures came in at 8876.39% (Q4 2024), 9988.22% (Q3 2024), and 6517.01% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -429.96% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 13.24% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 32.62% |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8,876.39% |
| Sep 30, 2024 | -9,988.22% |
| Jun 30, 2024 | -6,517.01% |
| Mar 31, 2024 | -0.63% |
| Dec 31, 2023 | 17.37% |
| Sep 30, 2023 | -5.38% |
| Jun 30, 2023 | 7.69% |
| Mar 31, 2023 | -6.29% |
| Dec 31, 2022 | -232.06% |
| Sep 30, 2022 | -7,959.23% |
| Sep 30, 2021 | -7,374.74% |